Alan Fuhrman's Net Worth
$1.21 Million
Who is Alan Fuhrman?
Alan Fuhrman has an estimated net worth of $1.21 Million. This is based on reported shares across multiple companies, which include Esperion Therapeutics, Inc., SpringWorks Therapeutics, Inc., Loxo Oncology, Inc., Checkmate Pharmaceuticals, Inc., Mirna Therapeutics, Inc., SONUS PHARMACEUTICALS INC, Tyra Biosciences, Inc., and AMBIT BIOSCIENCES CORP.
SEC CIK
Alan Fuhrman's CIK is 0001303521
Past Insider Trading and Trends
2023 was Alan Fuhrman's most active year for acquiring shares with 8 total transactions. Alan Fuhrman's most active month to acquire stocks was the month of April. 2014 was Alan Fuhrman's most active year for disposing of shares, totalling 5 transactions. Alan Fuhrman's most active month to dispose stocks was the month of January. 2018 saw Alan Fuhrman paying a total of $29,793.75 for 11,375 shares, this is the most they've acquired in one year. In 2019 Alan Fuhrman cashed out on 48,374 shares for a total of $11,367,890.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Esperion Therapeutics, Inc. (ESPR) Snapshot price: $1.69
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +75.65% | 23K |
—
|
—
| 53.4K |
May 23
| |||
Form 4
| +20.39% | 5.15K |
—
|
—
| 30.4K |
Jun 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 26
| |||
Form 4
| +96.10% | 12.38K |
—
|
—
| 25.25K |
May 27
| |||
Form 4
| +10.47% | 1.22K |
—
|
—
| 12.88K |
May 28
| |||
Form 4
| +1,682.42% | 11K |
—
|
—
| 11.66K |
May 15
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
SpringWorks Therapeutics, Inc. (SWTX) Snapshot price: $38.75
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +38.73% | 4.09K |
—
|
—
| 14.67K |
May 16
| |||
Form 4
| +78.46% | 4.65K |
—
|
—
| 10.57K |
May 24
| |||
Form 4
| +435.62% | 4.82K |
—
|
—
| 5.92K |
May 19
| |||
Form 4
| +4.59% | 1.11K |
—
|
—
| 25.23K |
May 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Loxo Oncology, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 13
| |||
Form 4
|
—
|
0
|
$94.71 | -$437,642.89 |
0
|
Jun 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Checkmate Pharmaceuticals, Inc. No price found
See Remarks
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Mirna Therapeutics, Inc. (SYBX) Snapshot price: $1.58
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||